Short Interest in Carisma Therapeutics, Inc. (NASDAQ:CARM) Decreases By 5.4%

Carisma Therapeutics, Inc. (NASDAQ:CARM) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 537,700 shares, a decline of 5.4% from the December 15th total of 568,400 shares. Based on an average daily volume of 252,500 shares, the days-to-cover ratio is currently 2.1 days. Currently, 2.5% of the company’s stock are short sold.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CARM. HC Wainwright reaffirmed a “neutral” rating on shares of Carisma Therapeutics in a report on Monday, December 16th. Robert W. Baird cut Carisma Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $10.00 to $1.00 in a research report on Thursday, December 12th. EF Hutton Acquisition Co. I upgraded shares of Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. D. Boral Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Carisma Therapeutics in a report on Monday, January 13th. Finally, Baird R W cut shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Five research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $4.94.

Institutional Investors Weigh In On Carisma Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC increased its holdings in Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares during the last quarter. Wexford Capital LP raised its position in Carisma Therapeutics by 75.5% during the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after purchasing an additional 15,000 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Carisma Therapeutics in the second quarter worth $40,000. 44.27% of the stock is owned by institutional investors.

Carisma Therapeutics Stock Performance

Shares of NASDAQ:CARM traded down $0.02 during mid-day trading on Friday, reaching $0.44. 162,806 shares of the company traded hands, compared to its average volume of 341,444. Carisma Therapeutics has a 52 week low of $0.38 and a 52 week high of $2.77. The firm has a market cap of $18.40 million, a PE ratio of -0.28 and a beta of 1.56. The company’s 50 day moving average price is $0.63 and its 200-day moving average price is $0.90. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23.

Carisma Therapeutics (NASDAQ:CARM) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.31). Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. The firm had revenue of $3.39 million during the quarter. On average, equities analysts expect that Carisma Therapeutics will post -1.32 EPS for the current fiscal year.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.